drotrecogin alfa, activated (Xigris) Report issue

Active Ingredient History

  • Now
Drotrecogin alfa (activated) (Xigris, marketed by Eli Lilly and Company) is a recombinant form of human activated protein C that has anti-thrombotic, anti-inflammatory, and profibrinolytic properties. Drotrecogin alpha (activated) belongs to the class of serine proteases. Drotrecogin alfa has not been found to improve outcomes in people with severe sepsis. The manufacturer's aggressive strategies in marketing its use in severe sepsis have been criticized. On October 25, 2011, Eli Lilly & Co. withdrew Xigris from the market after a major study showed no efficacy for the treatment of sepsis.   Wikipedia

More Chemistry
activated protein c | autoprothrombin iia | blood coagulation factor xiv | blood coagulation factor xiv (human) | ceprotin | drotrecogin alfa | drotrecogin-alfa | drotrecogin alfa activated | drotrecogin alfa (activated) | drotrecogin alfa, activated | drotrecogin alfa (activated), lyophilized | drotrecognin alpha | human activated protein c | human protein c | protein c | protein c (coagulation inhibitor) | protein c concentrate | protein c concentrate human | protein c concentrate (human) | protein c human | recombinant human activated protein c (rh-apc) | rhapc | xigris


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue